Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) shares hit a new 52-week high on Tuesday . The stock traded as high as $14.05 and last traded at $13.96, with a volume of 1134132 shares trading hands. The stock had previously closed at $13.20.
Silverback Therapeutics Price Performance
The stock has a market capitalization of $468.03 million, a price-to-earnings ratio of -5.77 and a beta of 0.60. The stock’s 50 day simple moving average is $10.71 and its 200-day simple moving average is $9.46.
About Silverback Therapeutics
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Read More
- Five stocks we like better than Silverback Therapeutics
- What Are Dividend Achievers? An Introduction
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- EV Stocks and How to Profit from Them
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
